Rheumatology Advance Access originally published online on September 20, 2004
Rheumatology 2005 44(1):83-88; doi:10.1093/rheumatology/keh404
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology Vol. 44 No. 1 © British Society for Rheumatology 2004; all rights reserved
PAPER |
Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis
1 Division of Clinical Immunology, Third Department of Internal Medicine, Medical and Health Science Center, University of Debrecen, Debrecen and 2 Second Department of Pediatrics, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Correspondence to: A. Ponyi, Third Department of Internal Medicine, Division of Clinical Immunology, Medical and Health Science Center, University of Debrecen, 4004 Debrecen, Móricz Zs Krt 22, Hungary. E-mail: ponyi{at}gyer2.sote.hu
Objectives. To present the outcome of patients with idiopathic inflammatory myositis, focusing on functional ability and quality of life.
Methods. Analysis was performed using data from 105 adult patients with definitive polymyositis, dermatomyositis or overlap myositis, who were followed up at a single centre. The diagnosis was made between 1979 and 2000 based on Bohan and Peter's criteria. Functional ability was assessed after a minimum follow-up of 3 yr with the Health Assessment Questionnaire Disability Index (HAQDI) and quality of life was measured with the Short Form 36-item questionnaire (SF-36).
Results. Fifteen patients in our cohort died and 87 participated in the evaluation of functional outcome. Functional ability after a median follow-up of 107.1 months (range 36.4–273.3) was heterogeneous. The median HAQDI score was 0.875 (range 0–2.875). Polyphasic or chronic–progressive disease course, osteoporosis and long-term follow-up were predictive of higher HAQDI scores. In terms of quality of life, significant differences from population norms were shown in all domains of the SF-36. There were no significant differences in the SF-36 scores among the patients according to clinicopathological subset or disease course.
Conclusions. Although the mortality of our cohort was favourable, myositis continues to have a great impact on life in the medium and long term. The present work indicates that myositis patients have a significantly poorer quality of life than the normal population, but there was no difference among the patients according to clinicopathological subsets.
KEY WORDS: Dermatomyositis, Outcome, Overlap myositis, Polymyositis, Quality of life
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. O. Harris-Love, J. A. Shrader, D. Koziol, N. Pahlajani, M. Jain, M. Smith, H. L. Cintas, C. L. McGarvey, L. James-Newton, A. Pokrovnichka, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis Rheumatology, February 1, 2009; 48(2): 134 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I M Bronner, M F G van der Meulen, M de Visser, S Kalmijn, W J van Venrooij, A E Voskuyl, H J Dinant, W H J P Linssen, J H J Wokke, and J E Hoogendijk Long-term outcome in polymyositis and dermatomyositis Ann Rheum Dis, November 1, 2006; 65(11): 1456 - 1461. [Abstract] [Full Text] [PDF]
|
|